FDA Finalizes Its Mandatory Cosmetics Recall Playbook: What Foreign Brands Need to Know

By /

By Vincent Cruz

On October 22, 2026, the U.S. Food and Drug Administration (FDA) issued the final version of its guidance “Questions and Answers Regarding Mandatory Cosmetics Recalls: Guidance for Industry.” It is the clearest explanation yet of how FDA will use one of MoCRA’s strongest powers: ordering a cosmetics recall itself, instead of only asking a company to recall a product voluntarily. MoCRA is the Modernization of Cosmetics Regulation Act of 2022.

This is guidance, not a recall of any specific product, and no brand is named in it. FDA published the document in draft form on December 18, 2025, received seven public comments, and has now finalized it with no substantive changes (Federal Register notice, October 23, 2026; Docket No. FDA-2025-D-2246). Guidance itself is nonbinding — it states FDA’s current thinking — but the authority it explains comes from the law, section 611 of the Federal Food, Drug, and Cosmetic Act, and an order issued under that section must be followed.

When can FDA order a recall?

FDA must first find two things: a reasonable probability that the cosmetic is adulterated or misbranded under the law, and a reasonable probability that using or being exposed to it will cause serious adverse health consequences or death — the standard FDA shortens to “SAHCOD.” Serious harm includes death, hospitalisation, infection, and significant disfigurement such as serious burns or significant hair loss.

Some grounds FDA lists connect directly to duties foreign brands already have under MoCRA. A product can be adulterated if it was made under conditions that do not meet good manufacturing practice requirements, or if it or its ingredients lack adequate safety substantiation. It can be misbranded if its labelling is false or misleading, or if required label information — including the adverse-event reporting contact — is missing or unclear.

How the process works

FDA does not start with an order. It first notifies the responsible person in writing — for most foreign brands, the company whose name appears on the label — and gives them a chance to stop distribution and recall the product voluntarily, in the time and manner FDA sets. FDA says it still expects most problem products to be handled this voluntary way.

If the company does not act, FDA may order it to stop distributing the product immediately. The company then gets an informal hearing, held within 10 days of the order, where it can argue the evidence does not support the order. After the hearing, FDA can cancel the order, keep it in place, or strengthen it into a full recall order with notification duties, a timetable, and a schedule for updating FDA. Only the FDA Commissioner can issue or cancel a recall order. FDA may also require notice to everyone who made, distributed, imported, or sold the product, and to the public — and FDA will publish its own press release naming the product and the risk. Ignoring an order is a prohibited act and can lead to an injunction or criminal prosecution.

The evidence FDA may weigh includes inspection findings, laboratory results, injury data, serious adverse event reports, complaints, how vulnerable the product’s users are (for example infants or pregnant women), and whether the company acted voluntarily when first asked.

Two scope points matter for importers: the authority covers products that meet the legal definition of a cosmetic (soap is excluded), but not products regulated as both a cosmetic and a drug — those face different recall authorities.

What foreign brands should do now

There is nothing to file because of this guidance, and no new deadline. What it changes is the cost of being unprepared. Check four things while nothing is wrong: (1) your safety substantiation records are complete and easy to retrieve; (2) your factory’s manufacturing records would stand up to an FDA inspection; (3) the adverse-event contact on your labels reaches a real person who can act quickly, and your adverse event and complaint records are in order; and (4) you have a written recall plan naming who stops shipments, who notifies your U.S. distributors and retailers, and who speaks to FDA — FDA’s first letter goes to the name on the label, and its hearing clock is only 10 days. Foreign facilities should also confirm their U.S. agent details in their FDA registration are current, so an FDA notice never goes to a stale contact.

Official sources:

Next steps: Not sure whether your brand’s MoCRA house is in order? Start with our free MoCRA checklist — then check whether your facility needs a U.S. agent with our eligibility checker.

Powered by
Scroll to Top